03 September 2016
A new report by visiongain predicts that the worldwide market for biotech API manufacturing services market will reach $4.36bn in 2016. This forecast and others appears in Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine published in August 2016. Visiongain is a business information provider in London, UK.
Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2015 to 2026 for the biotech API manufacturing services market, as well as for therapeutic applications.
“The outsourcing of biotech API contract manufacturing to contract manufacturing organizations around the world offers a number of benefits. As pharmaceutical companies around the world aim to cut costs in an increasingly crowded market CMOs offer scheduled and affordable services; without the high cost associated with building new manufacturing facilities. Contract manufacturing organizations also benefit smaller pharmaceutical companies, who outsource to access expertise and gain entry to markets they otherwise would not be able to reach; particular in emerging nations where the industry is on a rapid rise. Ultimately biotech API contract manufacturing helps to increase the interconnected nature of the pharmaceutical industry benefiting a number of groups as in continues to grow in the ever expanding pharmaceutical industry. “
- Arvind Deol, pharmaceutical market analyst, visiongain, 2016
The report will focus on the five main segments of the market:
• Monoclonal antibody (mAb) therapies
• Insulin therapies
• Interferon therapies
• Growth hormones.
This independent, 238-page report guarantees you will remain better informed than your competition. With 135 tables and figures examining the Biological API Manufacturing market space, the report gives you a visual, one-stop breakdown of your market.
Our work also shows individual revenue forecasts to 2026 for these national markets:
• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market